Home | Add Company | Subscribe | Search | Contact





Add Company

Your company can benefit from enhanced listings. Questions? Read our FAQ first.


Personalized notification service and newsletter info

Subscribe (free) to get notified of new additions.


Learn more About us and about our Services


Contact us

drug developmentand patent

HEALTHPOINT Ltd. Receives Patent Application Notice of Allowance for Trademarked XENADERM™ Ointment Vehicle

Concerns: drug developmentand patent
Released on: 27-Sep-2002

Pharmaceutical form and dosage: Ointment

Packaging: 60 gram tubes


- Devices
- Drug delivery
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)
- Preventive

Therapeutic target:

- Aging
- Cancer
- Dermatology
- Geriatrics
- Infectious Diseases
- Orthopedics
- Pain
- Surgery
- Transplant

Concerns the following market:
- United States of America

See also

Company Profile: Healthpoint, Ltd., a DFB Pharmaceuticals Company
United States of America

Contact for this news release: Jay Nisbet

Or check this company's:

Full Description:
(Fort Worth, Texas, USA) — Paul Dorman, CEO and Chairman of DFB Pharmaceuticals, Inc. and Healthpoint Ltd., has announced that the United States Patent and Trademark Office has granted Healthpoint a Notice of Allowance on its patent application for the ointment vehicle that is the basis for Healthpoint’s Xenaderm™, a prescription-only ointment that promotes healing and acts as a protective covering for wounds.

Lead inventor was David Jones, a Senior Scientific Advisor in the Research and Development division of Healthpoint.

“Mr. Jones and his group are to be applauded for continuing to develop a very impressive body of patented technology and related intellectual property for our companies,” said Mr. Dorman.

According to the company, the ointment can be used with a wide range of drug active ingredients and will serve as a vehicle for other drug actives in the future, replacing the use of petroleum-based ointments.

“Formulated to promote healing and to act as a protective covering, Xenaderm eliminates patients’ needs for multiple products,” said Scott Goodridge, Healthpoint’s Marketing Manager for Skin Management Products.

Xenaderm, distributed in 60-gram tubes, physiologically stimulates the capillary bed increasing circulation in the wound site, improves epithelialization by reducing premature epithelial desiccation, and can act as a protective covering for wounds.

Healthpoint, Ltd. is a North American market leader in innovative tissue management, dermatology, and infection prevention. A DFB Pharmaceuticals, Inc. affiliate company, Healthpoint has headquarters in Fort Worth, Texas, USA. Visit Healthpoint’s web site at www.healthpoint.com.

DFB, through its affiliate companies, contract partners, and branded marketing organizations, provides technology-driven products, outsourcing services and in-licensing and out-licensing opportunities to the healthcare industry worldwide.


  Contact for this news release: Jay Nisbet

Suggestion box | Disclaimer | Privacy Policy | Rules & Regulations
Copyright© Cofidei, Inc. Page Last modified: 27-Sep-2002.

Home | Add Company | Subscribe to Newsletter | Search Companies | Search Offers | Power search